PT2147122E - Terapia enzimática antitumoral - Google Patents
Terapia enzimática antitumoral Download PDFInfo
- Publication number
- PT2147122E PT2147122E PT87549101T PT08754910T PT2147122E PT 2147122 E PT2147122 E PT 2147122E PT 87549101 T PT87549101 T PT 87549101T PT 08754910 T PT08754910 T PT 08754910T PT 2147122 E PT2147122 E PT 2147122E
- Authority
- PT
- Portugal
- Prior art keywords
- anticancer therapy
- enzymatic
- enzymatic anticancer
- therapy
- anticancer
- Prior art date
Links
- 238000011319 anticancer therapy Methods 0.000 title 1
- 230000002255 enzymatic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91303907P | 2007-04-20 | 2007-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2147122E true PT2147122E (pt) | 2014-10-15 |
Family
ID=39875909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87549101T PT2147122E (pt) | 2007-04-20 | 2008-04-18 | Terapia enzimática antitumoral |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741283B2 (enExample) |
| EP (1) | EP2147122B1 (enExample) |
| JP (1) | JP5595904B2 (enExample) |
| KR (1) | KR101540296B1 (enExample) |
| CN (1) | CN101680039B (enExample) |
| BR (1) | BRPI0810384B8 (enExample) |
| CA (1) | CA2684749C (enExample) |
| CY (1) | CY1117000T1 (enExample) |
| DK (1) | DK2147122T3 (enExample) |
| ES (1) | ES2507508T3 (enExample) |
| HR (1) | HRP20140947T1 (enExample) |
| IL (1) | IL201593A (enExample) |
| MX (1) | MX2009011320A (enExample) |
| NZ (1) | NZ580980A (enExample) |
| PL (1) | PL2147122T3 (enExample) |
| PT (1) | PT2147122E (enExample) |
| SI (1) | SI2147122T1 (enExample) |
| TW (1) | TWI486169B (enExample) |
| WO (1) | WO2008131163A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534300T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| HUE027603T2 (en) | 2007-04-20 | 2016-10-28 | Sigma-Tau Rare Disease Ltd | Stable, recombinant adenosine deaminase |
| AU2012212023B9 (en) * | 2011-02-03 | 2017-01-12 | Mirna Therapeutics, Inc. | Synthetic mimics of miR-34 |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| WO2016191283A2 (en) * | 2015-05-22 | 2016-12-01 | University Of Houston System | Enzymatic immunomodulation of solid tumors and user thereof |
| US20190343935A1 (en) * | 2016-03-11 | 2019-11-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for treating tumors |
| KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| CA3116138A1 (en) | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| EP4430195A4 (en) * | 2021-11-12 | 2025-09-24 | Georgia Tech Res Inst | ADENOSINE DEAMINASE 1 COMPOSITIONS AND METHODS OF USE THEREOF |
| US20240250753A1 (en) * | 2022-10-10 | 2024-07-25 | Berkeley Marine Robotics Inc. | Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5346823A (en) * | 1984-05-29 | 1994-09-13 | Genencor, Inc. | Subtilisin modifications to enhance oxidative stability |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
| US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5756593A (en) * | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| WO1999030727A1 (en) * | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
| US6333396B1 (en) * | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| US20020088017A1 (en) * | 1999-04-28 | 2002-07-04 | Board Of Regents, The University Of Texas System | Adenosine deaminase deficient transgenic mice and methods for the use thereof |
| US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| AU7868400A (en) | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
| WO2002077233A2 (en) * | 2000-11-08 | 2002-10-03 | Millennium Pharmaceuticals, Inc. | 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF |
| KR20030043780A (ko) * | 2001-11-28 | 2003-06-02 | 주식회사 바이오폴리메드 | 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법 |
| JP2005516917A (ja) * | 2001-12-12 | 2005-06-09 | アメリカ合衆国 | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 |
| US7122189B2 (en) * | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US7413738B2 (en) * | 2002-08-13 | 2008-08-19 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on biodegradable linkers |
| US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US20040175804A1 (en) * | 2003-03-04 | 2004-09-09 | Skonezny Paul M. | Process for preparing dideoxyinosine using adenosine deaminase enzyme |
| US7301003B2 (en) * | 2005-08-26 | 2007-11-27 | Enzon Pharmaceuticals, Inc. | Method of preparing polymers having terminal amine groups |
| US7601798B2 (en) * | 2005-10-04 | 2009-10-13 | Enzon Pharmaceuticals, Inc. | Methods of preparing polymers having terminal amine groups using protected amine salts |
| US7989554B2 (en) * | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
| WO2007149686A2 (en) | 2006-06-21 | 2007-12-27 | Enzon Pharmaceuticals, Inc. | Stabilized proteins |
| CA2662962A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polyalkylene oxides having hindered ester-based biodegradable linkers |
| JP2010514803A (ja) * | 2006-12-29 | 2010-05-06 | エンゾン ファーマスーティカルズ インコーポレイテッド | 肺疾患を治療するためのアデノシンデアミナーゼの使用方法 |
| HUE027603T2 (en) | 2007-04-20 | 2016-10-28 | Sigma-Tau Rare Disease Ltd | Stable, recombinant adenosine deaminase |
-
2008
- 2008-04-18 PL PL08754910T patent/PL2147122T3/pl unknown
- 2008-04-18 CA CA2684749A patent/CA2684749C/en not_active Expired - Fee Related
- 2008-04-18 NZ NZ580980A patent/NZ580980A/en unknown
- 2008-04-18 HR HRP20140947AT patent/HRP20140947T1/hr unknown
- 2008-04-18 JP JP2010504262A patent/JP5595904B2/ja active Active
- 2008-04-18 US US12/105,682 patent/US8741283B2/en active Active
- 2008-04-18 WO PCT/US2008/060733 patent/WO2008131163A1/en not_active Ceased
- 2008-04-18 EP EP08754910.1A patent/EP2147122B1/en active Active
- 2008-04-18 MX MX2009011320A patent/MX2009011320A/es active IP Right Grant
- 2008-04-18 KR KR1020097023239A patent/KR101540296B1/ko active Active
- 2008-04-18 DK DK08754910.1T patent/DK2147122T3/da active
- 2008-04-18 ES ES08754910.1T patent/ES2507508T3/es active Active
- 2008-04-18 TW TW097114405A patent/TWI486169B/zh active
- 2008-04-18 PT PT87549101T patent/PT2147122E/pt unknown
- 2008-04-18 SI SI200831301T patent/SI2147122T1/sl unknown
- 2008-04-18 CN CN200880021105.8A patent/CN101680039B/zh active Active
- 2008-04-18 BR BRPI0810384A patent/BRPI0810384B8/pt active IP Right Grant
-
2009
- 2009-10-18 IL IL201593A patent/IL201593A/en active IP Right Grant
-
2014
- 2014-10-03 CY CY20141100797T patent/CY1117000T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0810384B8 (pt) | 2021-05-25 |
| CN101680039B (zh) | 2016-08-24 |
| BRPI0810384B1 (pt) | 2021-02-02 |
| BRPI0810384A2 (pt) | 2014-11-04 |
| EP2147122A1 (en) | 2010-01-27 |
| IL201593A0 (en) | 2010-05-31 |
| HRP20140947T1 (hr) | 2015-02-13 |
| CA2684749C (en) | 2016-06-21 |
| TWI486169B (zh) | 2015-06-01 |
| CN101680039A (zh) | 2010-03-24 |
| PL2147122T3 (pl) | 2015-05-29 |
| IL201593A (en) | 2017-07-31 |
| WO2008131163A8 (en) | 2010-01-28 |
| KR101540296B1 (ko) | 2015-07-31 |
| NZ580980A (en) | 2012-04-27 |
| TW200902051A (en) | 2009-01-16 |
| CY1117000T1 (el) | 2017-04-05 |
| EP2147122A4 (en) | 2010-11-17 |
| SI2147122T1 (sl) | 2015-01-30 |
| MX2009011320A (es) | 2009-12-15 |
| US20090047270A1 (en) | 2009-02-19 |
| WO2008131163A1 (en) | 2008-10-30 |
| DK2147122T3 (da) | 2014-10-13 |
| EP2147122B1 (en) | 2014-07-16 |
| JP2010524968A (ja) | 2010-07-22 |
| US8741283B2 (en) | 2014-06-03 |
| AU2008242791A1 (en) | 2008-10-30 |
| KR20090130108A (ko) | 2009-12-17 |
| CA2684749A1 (en) | 2008-10-30 |
| JP5595904B2 (ja) | 2014-09-24 |
| ES2507508T3 (es) | 2014-10-15 |
| RU2009142817A (ru) | 2011-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL206654A0 (en) | Combination therapy | |
| GB0712494D0 (en) | Substrate reduction therapy | |
| GB0715346D0 (en) | Stimulator | |
| IL199992A0 (en) | Combination therapy | |
| SI2147122T1 (sl) | Encimatska terapija proti raku | |
| EP2054061A4 (en) | COMBINATION THERAPY | |
| GB0719518D0 (en) | Therapy | |
| EP2211863A4 (en) | COMBINATION THERAPY | |
| IL208001A0 (en) | Improved anticancer treatments | |
| GB0700284D0 (en) | Combination therapy | |
| GB0803948D0 (en) | Combination therapy | |
| GB0700635D0 (en) | Therapy | |
| GB0716072D0 (en) | Therapy | |
| GB0707429D0 (en) | HIV Therapy | |
| GB0710043D0 (en) | Anticancer treatments | |
| GB0708693D0 (en) | Anticancer treatments | |
| GB0703963D0 (en) | Therapy | |
| GB0705917D0 (en) | Therapy | |
| AU2008903284A0 (en) | Combination therapy | |
| HK1140958A (en) | Combination therapy | |
| GB0813292D0 (en) | Therapy | |
| GB0812659D0 (en) | Therapy | |
| AU2008902139A0 (en) | HLST Therapy | |
| AU2008902090A0 (en) | Cancer Therapy | |
| AU2009905152A0 (en) | Combination therapy |